| Autor: |
Eva Bednarski, Perla M. Del Rio Estrada, Justin DaSilva, Celia Boukadida, Fengwen Zhang, Yara A. Luna-Villalobos, Ximena Rodríguez-Rangel, Elvira Pitén-Isidro, Edgar Luna-García, Dafne Díaz Rivera, Dulce M. López-Sánchez, Daniela Tapia-Trejo, Maribel Soto-Nava, Myriam Astorga-Castañeda, José O. Martínez-Moreno, Guadalupe S. Urbina-Granados, José A. Jiménez-Jacinto, Francisco J. Serna Alvarado, Yerania E. Enriquez-López, Oliva López-Arellano, Gustavo Reyes-Teran, Paul D. Bieniasz, Santiago Avila-Rios, Theodora Hatziioannou |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
mBio, Vol 13, Iss 4 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2150-7511 |
| DOI: |
10.1128/mbio.00840-22 |
| Popis: |
ABSTRACT Global population immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is accumulating through heterogeneous combinations of infection and vaccination. Vaccine distribution in low- and middle-income countries has been variable and reliant on diverse vaccine platforms. We studied B-cell immunity in Mexico, a middle-income country where five different vaccines have been deployed to populations with high SARS-CoV-2 incidences. Levels of antibodies that bound a stabilized prefusion spike trimer, neutralizing antibody titers, and memory B-cell expansion correlated with each other across vaccine platforms. Nevertheless, the vaccines elicited variable levels of B-cell immunity, and the majority of recipients had undetectable neutralizing activity against the recently emergent omicron variant. SARS-CoV-2 infection, experienced before or after vaccination, potentiated B-cell immune responses and enabled the generation of neutralizing activity against omicron and SARS-CoV for all vaccines in nearly all individuals. These findings suggest that broad population immunity to SARS-CoV-2 will eventually be achieved but by heterogeneous paths. IMPORTANCE The majority of studies on SARS-CoV-2 vaccine-elicited immunity and immune evasion have focused on single vaccines corresponding to those distributed in high-income countries. However, in low- and middle-income countries, vaccine deployment has been far less uniform. It is therefore important to determine the levels of immunity elicited by vaccines that have been deployed globally. Such data should help inform policy. Thus, this paper is very much a “real-world” study that focuses on a middle-income country, Mexico, in which five different vaccines based on mRNA, adenovirus, and inactivated-virus platforms have been extensively deployed, while (as documented in our study) SARS-CoV-2 variants with increasing degrees of immune evasiveness have propagated in the Mexican population, culminating in the recent emergence of B.1.1.529 (omicron). |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
